An important mechanism for the antiinflammatory effect of pharmacological doses of glucocorticoids is the inhibition of arachidonic acid release from phospholipids by phospholipase A2 (PLA2). As a corollary, one might predict that low endogenous concentrations of glucocorticoids favor inflammatory disease states. Indeed, clinical and experimental observations revealed an association between glucocorticoid deficiency and disease states caused by immunological and/or inflammatory mechanisms. The purpose of the present investigation was to study the regulation of PLA2 mRNA, protein, and enzyme activity in adrenalectomized (ADX) rats where glucocorticoid concentrations were below physiological levels. The mRNA of group I and II PLA2 were measured by PCR. Group II PLA2 mRNA was increased by 126±9% in lung tissue of ADX rats, whereas group I PLA2 was increased only by 27±1.5%. The increase in group II mRNA in ADX rats was reflected by a corresponding increase of group II PLA2 protein (70-100%) in lung, spleen, liver, and kidney. This increase was reversed by the administration of exogenous corticosterone. After ADX, the percentage increase in total PLA2 activity was higher than that of mRNA or PLA2 protein, suggesting that the activity of the enzyme was modulated by inhibitors or activators. The concentration of lipocortin-I, an inhibitor of PLA2 enzyme was strongly correlated with the activity of PLA2 in the tissues (lung, spleen, liver, and kidney). In all these tissues, the concentrations of lipocortin-I declined after ADX. Thus upregulation of PLA2 enzyme and downregulation of lipocortin-I might account for the enhanced inflammatory response in hypoglucocorticoid states. (J. Clin. Invest. 1993Invest. . 92:1974Invest. -1980
Introduction
The biological and clinical relevance of high endogenous or exogenous glucocorticoid concentrations in mammals has been widely discussed (1) (2) (3) (4) . During stress, for example, increased concentrations of glucocorticoid hormones were hypothesized to turn off the defensive inflammatory reactions that may overshoot after noxious stimuli (4) . This effect is used in clinical practice by prescribing pharmacological doses of glucocorticoids to patients with inflammatory diseases. The antiinflammatory effect of glucocorticoids is mediated through a number of mechanisms, among which the inhibition of eicosanoid production by phospholipase A2 (PLA2)' enzyme appears to play a key role (5) . PLA2 enzymes characterized so far are classified into group I and group II based on their primary and secondary structures (6) . Group II (but not group I PLA2) has been suggested to be involved in the pathogenesis ofinflammatory reactions (7-1 1 ). Several lines of evidence reveal that high doses of glucocorticoids decrease PLA2 activity by two different mechanisms: (a) by generating proteins such as lipocortin-I, which were shown to inhibit PLA2 activity in vitro (for a review, see reference 5 ), through mechanisms that are not yet well defined (12) (13) , and (b) by reducing the expression of group II PLA2 enzyme (14) (15) .
In contrast to the high glucocorticoid levels, the relevance of abnormally low endogenous glucocorticoid concentrations to the inflammatory response has rarely been addressed. Previous investigations have shown an increased duration and magnitude of inflammatory reactions and higher concentrations of various prostaglandins after adrenalectomy (ADX) or treatment with a glucocorticoid receptor antagonist in animals (16) (17) (18) (19) (20) . It was hypothesized that the increased concentrations of prostaglandins were caused by an increased activity of PLA2 ( 17, 20) . In the present study, we report the effect of glucocorticoid deficiency induced by ADX in rats on mRNA, protein levels of group II PLA2, and total enzyme activity of PLA2 in different tissues. The results revealed an upregulation of group II PLA2 after ADX, which was reversed after the administration of corticosterone.
Methods
Preparation ofADX rats. ADX with and without replacement of corticosterone pellets and sham-operated ADX (SHAM-ADX) were performed as described previously (21 ). Male Sprague Dawley rats, weighing 160-180 g (Holtzman Laboratory Animals, Madison, WI), were kept in a temperature-, humidity-, and light ( 12 h on)-controlled room and were allowed food and water ad libitum. The rats were anesthetized with ether and treated in the following ways: Group 1: SHAM-ADX. Adrenal glands were exposed but not touched. Group 2: SHAM-ADX + V. Adrenal glands were exposed but not touched (vehicle [ After surgery, all rats were provided with 0.5% saline for their drinking solution. Starting on the evening after the surgery, all rats, except those in group 4, were injected with DMSO three times a day to act as controls for a separate experiment. When the plasma adrenocorticotropic hormone and corticosterone concentrations were analyzed in the SHAM-ADX rats that received either subcutaneous injections of DMSO or no injections, there were no differences, indicating that the stress involved with the injections did not affect corticosteroid concentrations. On the morning and evening ofthe 5th d after the surgery, the rats were decapitated, and lung, spleen, kidney, and liver tissues were collected, immediately frozen in liquid nitrogen, and stored at -80'C until further use. This protocol was approved by the University ofCalifornia, San Francisco Committee on Animal Research.
RNA extraction and modification ofgroup II PLA2 transcript. Total RNA from the tissues of different experimental rats was extracted by the lithium chloride-urea procedure (22) (27) . The protein concentration was determined using the bicinchonic acid protein assay reagent (Pierce Chemical Co., Rockford, IL).
Western blotting. For Western blots, 2-10 Mg of total protein (these protein samples were not boiled, and the treatment buffer did not contain any reducing agents) were loaded and resolved on a 12.5% SDSpolyacrylamide gel (28) . The proteins were transferred to nitrocellulose membrane by electroblot using Tris-glycine buffer containing 20% methanol. The transfer was performed at a constant voltage of 60 V for 60 min. Protein transfer was monitored by staining the nitrocellulose membrane with Ponceau S (Sigma Chemical Co., St. Louis, MO) and the gel with Coomassie blue. The blots were agitated with Tris-buffered saline (TBS), pH 7.5, containing 5% BSA for 60 min at room temperature, washed three times with TBS and incubated with primary antibody (2E7 and 2B9 hybridoma supernatants specific for group II PLA2 enzyme, a gift from Henk van den Bosch, State University of Utrecht, Utrecht, The Netherlands) diluted 1:5,000 in TBS containing 0.5% Tween 20 and 0.01% BSA. The incubation with monoclonal antibodies was performed for 4 hours at 370C. Membranes were washed three times with TBS containing 0.05% Tween 20 and incubated with peroxidase conjugated rabbit anti-mouse IgG (H + L) (Sigma Chemical Co.) for 1 h at room temperature diluted 1:6,000 in TBS containing 0.05% Tween 20 and 0.01% BSA. Membranes were washed three times with TBS containing 0.05% Tween 20 and three times with TBS only to remove Tween 20. After washing, the peroxidase activity was detected using the enhanced chemiluminescence Western blotting detection system (Amersham International, Aylesbury, Buckinghamshire, United Kingdom) according to the manufacturer's instructions. The bands on the x-ray films were scanned with a transmittance scanning densitometer (Camag TLC Scanner II; Camag, Muttenz, Switzerland) to get an absorbance profile across each band. The peak areas were weighed for measurements.
Assay of PLA2 activity. PLA2 activity was assayed using [3H]-oleate-labeled, autoclaved Escherichia coli as the substrate (29). The reaction mixture of 350 M1 contained 100 mM Tris-HCI pH 8.0; 5 mM Ca2 , 11.4 x 109 cells of autoclaved E. coli cells (corresponding to 10,000 cpm and 4.6 nmol phospholipid), and 0.3-70 Mug tissue acid extract. The amount of tissue protein was chosen such that 6-15% hydrolysis of substrate was obtained when incubated at 37°C for 30 min. The reaction was terminated by adding 100 M1u of 2 N hydrochloric acid. 100 ml of fatty acid-free BSA ( 100 mg/ml) was added, and the tubes were vortexed and centrifuged at 13,000 g for 5 min. An aliquot ( 140 Ml) of the supernatant containing released [3H ] oleic acid was mixed with scintillation cocktail (Dynagel, J. T. Baker, B. V. Deventer, Holland) and counted in a liquid scintillation counter.
Results
The mRNA of group II PLA2 was quantified by PCR using a constant amount of a modified group II cDNA transcript as an internal standard. Both specific target mRNA and internal standard were coamplified in one reaction using the same primers (24) . Fig. 1 shows the PCR products of group II PLA2 cDNA and the internal standard of rat lung tissue separated on an agarose gel; three concentrations of total RNA from control (SHAM-ADX) rats, SHAM-ADX + V, ADX + CORT, and ADX rats were used. Visual observation of the bands revealed that group II PLA2 mRNA was increased in ADX rat lungs compared with the values in the other three groups. Similar results were obtained in two additional experiments. The inclusion of an internal standard excluded the possibility that increased concentrations of group II PLA2 in ADX rats were caused by an artifact during the PCR amplification procedure (24) .
To assess quantitatively the effect ofADX on group II PLA2 mRNA, [ a-32p] dCTP was included during the PCR. The incorporation of radioactivity into group II PLA2 cDNA was determined at 20, 80, and 320 ng of RNA, with and without the internal standard (Fig. 2) . Three independent experiments re- vealed that the internal standard did not affect the generation of group II PLA2 cDNA. In all experiments, no significant difference in the group II PLA2 mRNA was observed between SHAM-ADX and SHAM-ADX + V groups (Fig. 2, A and B) . In ADX rats compared to SHAM-ADX + V rats, an increase of 126 ± 9% ofgroup II PLA2 mRNA was observed at 320 ng total RNA. In ADX rats substituted with glucocorticoids (ADX-CORT), group II PLA2 mRNA was decreased by 33±15% when compared with ADX rats. These results were furthermore supported by the analysis ofthe ratios ofcpm ofgroup II PLA2/cpm of internal standard. The results of one of three identical experiments are shown in Fig. 2 B. The impact of glucocorticoids on group I PLA2 has not been investigated previously. Therefore, we extended our study to group I PLA2 also. Quantitative studies with I a-32P]dCTPlabeled PCR products revealed that in ADX compared to SHAM-ADX + V rats, there was an increase of 27±1.5% of group I PLA2 mRNA (Fig. 3 A) . In all ADX rats treated with glucocorticoids (ADX + CORT) the levels of group I PLA2 mRNA decreased by 71±4% below that of control groups; no signal was detected on agarose gel after PCR (Fig. 3 A) .
To establish whether the increase ofgroup II PLA2 mRNA is associated with increased group II PLA2 protein, lung, spleen, liver, and kidney tissues were analyzed by Western blot using specific group II PLA2 monoclonal antibodies (Fig. 4, A  and B) . In all these tissue samples ADX resulted in an increased concentration of group II PLA2 protein ranging from 70 to 100% depending on the type oftissue analyzed (Fig. 4 B) . In these tissues of ADX rats substituted with glucocorticoids, group II PLA2 protein was decreased by 64-85%, when com- pared with ADX rats. In lung tissue, the percentage decline in protein was more pronounced (73%) than the corresponding decline of mRNA (33%). The reason for the very low PLA2 protein content in kidneys of SHAM-ADX is not clear. Activity ofPLA2 was assessed in tissues oflung, liver, spleen and kidney. For that purpose, the PLA2 enzyme was solubilized after acid extraction. The PLA2 enzyme extracted showed a pH optimum of 7.5-9.0 and required 5 mM Ca2+ for optimal activity. The results from PLA2 activity measurements are shown in Fig. 5 . Interestingly different tissues showed different amounts of PLA2 specific activity; lung tissue had the highest and kidney tissue the lowest PLA2 activity. In correlation with increased mRNA and PLA2 protein, the total PLA2 activity was also increased in the above studied tissues of ADX rats (Fig. 5) . In all the tissues analyzed, there was a threefold increase of PLA2 activity in ADX rats when compared with SHAM-ADX + V rats. The increased PLA2 activity was restored to normal level when ADX rats were substituted with glucocorticoids.
The relative increase in total PLA2 activity in ADX rats was twofold higher compared to the relative increase ofmRNA and protein suggesting that PLA2 activity is possibly modulated by changes in activators or inhibitors of PLA2. Lipocortin-I has shown to inhibit PLA2 activity (12, 13, 29) . Previously, we have reported decreased levels of lipocortin-I mRNA and protein in ADX rats and restoration of lipocortin-I to control levels in ADX rats treated with glucocorticoids (21 ). When the lipocortin-I concentrations were plotted next to the corresponding PLA2 activities (Fig. 5) , a correlation was observed: at higher concentrations oflipocortin-I, a decreased PLA2 activity was observed, and at lower concentrations oflipocortin-I an increased PLA2 was observed when the same organ was analyzed in different groups of rats.
Discussion

B
The quantitative RNA-PCR study revealed that both group I and group II PLA2 mRNA levels were elevated after ADX in lung tissue. The upregulation of PLA2 in ADX rats was not a nonspecific phenomenon, since the mRNA levels of other proteins (metallothionein-I1 and c-fos, c-myc, c-erbA(3 oncogenes) have been shown to remain unchanged (21). After ADX, the increase of mRNA of group II PLA2 was more pronounced than that of group I PLA2, and when the ADX rats were substituted with glucocorticoids, the mRNA of group II PLA2 was decreased less than that of group I PLA2, suggesting that group I PLA2 and group II PLA2 are regulated differently by glucocorticoids. Previous studies with rat vascular smooth vessel cells indicated that group II PLA2 mRNA was regulated by two different mechanisms: First, by cAMP as a second mesKidney senger, and second, by a cAMP-independent pathway ( 11). It has been shown that glucocorticoids inhibited cAMP-dependent, but not cAMP-independent expression of group II PLA2 mRNA ( 15) . Provided these in vitro studies reflect the in vivo situation, then one might assume that the inhibition of mRNA ofgroup II PLA2 by glucocorticoids in ADX rats was mediated by the cAMP pathway. Since the cAMP-independent pathway seems to be regulated by factors other than glucocorticoids ( 15) , the absence of a complete normalization of group II PLA2 mRNA in ADX rats with glucocorticoids is not surprising.
In lung tissue ofADX rats substituted with glucocorticoids, group II PLA2 protein was decreased by 73% when compared with ADX rats; this percentage decline in protein was more pronounced than the corresponding decline of 33% in mRNA, suggesting that glucocorticoids decrease group II PLA2 protein also by modulating posttranscriptional mechanisms. Separate transcriptional and posttranscriptional effects ofpharmacological doses of glucocorticoids have been reported in inflammatory conditions on the synthesis of group II PLA2, tumor necrosis factor, and interleukin-1 ( 14, 30, 31 ) .
The increases ofgroup II PLA2 protein and mRNA in ADX rats were also reflected by increases of PLA2 enzyme activity. The PLA2 enzyme activity measured in these tissues exhibited biochemical properties similar to group II PLA2 enzyme activity characterized from synovial fluid from rheumatoid patients and human platelets with regard to its optimum pH, Ca2' dependence, substrate preference, and also stability towards acidic pH (32) . The relative increase in total PLA2 activity was two-fold higher compared with the relative increase of mRNA and protein following ADX, suggesting that PLA2 activity was possibly modulated by an increase in activators or by removal of inhibitors. Lipocortins have been demonstrated to exhibit PLA2 inhibitory activity and to be regulated by glucocorticoids ( 1, 2, (33) (34) (35) . Previously, we have reported decreased levels of lipocortin-I mRNA and protein in ADX rats and restoration of lipocortin-I to control levels in ADX rats treated with glucocorticoids (21 ). When the lipocortin-I concentrations were plotted next to the corresponding PLA2 activities (Fig. 5) , a correlation was observed: at higher concentrations of lipocortin-I, a decreased PLA2 activity was observed, and at lower concentrations of lipocortin-I, an increased PLA2 activity was observed when the same organ was analyzed in different groups of rats. Moreover, the amount of lipocortin-I in different tissues was also related to the specific activity of PLA2 in the tissue; lungs contain large amounts of lipocortin-I and a high PLA2-specific activity, whereas kidney tissue has lower concentrations of lipocortin-I and also a lower PLA2 specific activity (Fig. 5) . Such correlations suggest lipocortin-I to be a modulator of in vivo PLA2 activity.
Lipocortin-I (sive calpactin-II) belongs to a group of proteins called annexins. Annexins, a widely distributed family of at least 12 cytoskeletal proteins capable of binding phospholipids in the presence of calcium, had been suggested to be mediators ofglucocorticoid action and to act as specific inhibitors of PLA2 ( 1, 2, [33] [34] [35] . Lipocortin-I has a distinct pattern of organ distribution (Fig. 5) and a discrete pattern of cellular distribution (36) . For example, lipocortin-I in skin is extremely abundant in the epidermis, especially in the basal keratinocytes, but sparse in the dermis (36) . There exists evidence that the synthesis of lipocortin-I can be induced in monocytes and differentiated macrophage-like cell lines by glucocorticoids (37) (38) (39) (40) (41) ; however, in certain other cell lines the synthesis of lipocortin-I does not appear to be regulated by glucocorticoids (42, 43) . Several pharmacological studies have used recombinant human lipocortin-I and derived peptide fragments in cell cultures and animal models. In these studies, lipocortin-I was demonstrated to inhibit inflammation (44) (45) , synthesis of platelet-activating factor (46), cytokine-mediated pyrogenesis (47) , and cerebral ischemia (48) . Thus potential exists for lipocortin-I to be an endogenous regulator of inflammation. However, the ability of lipocortin-I to inhibit the activity of PLA2 is still a controversial subject. Lipocortin-I is indeed an inhibitor of PLA2 in vitro (29), but only under conditions where lipocortin is not phosphorylated (49, 50), and the substrate or cofactor of the enzyme is limiting (12) . Furthermore, translocation experiments in a cell-free system or Xenopus oocytes revealed no evidence ofextracellular release oflipocortin-I, a prerequisite for the presumed extracellular site of action of lipocortin-I (51). Thus, although still controversial, the concept of lipocortin-I as a secreted protein, under the control of the hypothalamic-pituitary-adrenal axis yields, fresh insight into glucocorticoid regulation of inflammatory reactions (35) .
Apart from group I and group II PLA2 enzymes other PLA2 isozymes have been found in different tissues: (a) A Ca2+ -independent lysosomal PLA2 optimally active at acidic pH (52, 53) ; (b) a Ca2+-independent PLA2, active at neutral to basic pH (54, 55) ; (c) a Ca2+-dependent 85-kD PLA2 enzyme with a structure distinctly different from group I and group II PLA2 enzymes (56, 57) . The structure of both Ca2+-independent PLA2 enzymes is not known. Whether the 85-kD PLA2 enzyme is involved in inflammatory reactions has not been determined. Most likely, different isoforms of PLA2 enzymes may coexist in a single system, and might exert separately or cumulatively their effect in generating arachidonic acid. The other enzymes that generate arachidonic acid, depending on cell types are (a) sequential action of phospholipase C followed by diacylglycerol lipase or diacylglycerol kinase followed by phosphatidic acid specific PLA2; and (b) phospholipase D followed by phosphatidic acid specific PLA2 (58) . It is evident that glucocorticoids inhibit the release of arachidonic acid and subsequent formation of eicosanoids, no matter which class or type of phospholipase enzyme releases the arachidonic acid. The present investigation demonstrates that for restoration ofPLA2 activity by glucocorticoids in ADX rats, apart from regulating PLA2 enzyme at transcriptional and posttranscriptional level, an increase of an endogenous inhibitor is necessary. Lipocortin-I is a good candidate for such an inhibitory function, since lipocortin has been shown to inhibit Ca2+-independent PLA2 (52), phospholipase C (59), and phospholipase D (60) .
The majority of chronic inflammatory diseases are of unknown etiology, and the factors modulating their severity are largely unknown. Physiological endogenous glucocorticoid levels may protect from these disease states and low levels promote these disease states. The latter hypothesis was proposed in 1922 by Kepinov, who reported an increased sensitivity to bronchial anaphylactic reactions in ADX guinea pigs (16) . That observation was in line with the later findings ofan association between glucocorticoid deficiency and disease states explained by allergic and/or immunological mechanisms in experimental animals and humans (17, (61) (62) (63) (64) . The upregulation of group II PLA2 enzyme and the downregulation of lipocortin-I by low levels of glucocorticoids indicate that clinically unrecognized partial glucocorticoid deficiency, either caused by suppression of endogenous glucocorticoid production after withdrawal of exogenous glucocorticoids or caused low cortisol synthesis for other reasons, may be relevant for the genesis of inflammatory diseases.
